Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting

CONTEXT Chemotherapy-induced nausea and vomiting (CINV) can severely impair patients' quality of life (QOL). Psychotropics, especially olanzapine, have a strong antiemetic effect. OBJECTIVES To determine whether olanzapine could reduce the frequency of CINV and improve patients' QOL during chemotherapy. METHODS This was a randomized, double-blind, placebo-controlled trial. Forty-four patien...

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

BACKGROUND This study was designed to mainly evaluate the activity and safety of olanzapine compared with 5-hydroxytryptamine 3(5-HT3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). The second goal was to evaluate the impact of olanzapine on quality of life (QoL) of cancer pat...

Chemotherapy-induced nausea and vomiting: strategies for prevention and treatment.

Chemotherapy-induced nausea and vomiting.

younger patient age, platinumor anthracyclinebased chemotherapy, low alcohol consumption, earlier cycles of chemotherapy, previous history of morning sickness, and prior emetic episodes after chemotherapy. The acute and delayed scoring systems both had good predictive accuracy when applied to the external validation sample (acute— auroc: 0.69; 95% confidence interval: 0.59 to 0.79; delayed—auro...

Chemotherapy-induced nausea and vomiting.

Chemotherapy-induced nausea and vomiting (CINV) affects many cancer patients and has a great influence on quality of life. CINV involves coordination of several organs of the gastrointestinal tract, the peripheral and central nervous systems. Many neurotransmitters are involved in this process, and the predominant receptors are serotonin, neurokinin-1 and dopamine receptors. Risk factors for CI...